Related Experiment Video

Updated: May 27, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

miR221/222 in cancer: their role in tumor progression and response to therapy

M Garofalo1, C Quintavalle, G Romano

  • 1Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA.

Current Molecular Medicine
|November 16, 2011
PubMed

Insights

MicroRNAs (miRNAs) play a key role in cancer. Upregulated miR-221/222 can act as oncogenes or tumor suppressors, offering potential as prognostic and therapeutic cancer tools.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • MicroRNAs (miRNAs) are small non-coding RNAs regulating gene expression.
  • Aberrant miRNA expression is a hallmark of human cancers, affecting oncogenes and tumor suppressors.
  • miR-221 and miR-222 are homologous miRNAs frequently upregulated in various tumors.

Purpose of the Study:

  • To review the role of miR-221/222 in cancer progression.
  • To explore the potential of miR-221/222 as prognostic and therapeutic tools in oncology.

Main Methods:

  • Literature review of studies on miR-221/222 in cancer.
  • Analysis of miRNA dysregulation in tumor development.
  • Evaluation of gene therapy strategies involving miRNAs.

Main Results:

  • miR-221/222 exhibit dual roles as oncogenes or tumor suppressors depending on the cancer type.
  • Upregulation of miR-221/222 is observed in several human malignancies.
  • miRNA-based therapies, including silencing oncomiRs or re-expressing tumor suppressive miRNAs, are emerging strategies.

Conclusions:

  • miR-221/222 are significant players in cancer progression.
  • Targeting miR-221/222 holds promise for novel anti-cancer therapeutic approaches.
  • Further research into miR-221/222 functions can refine their use in integrated cancer therapy.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...